清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Single-Dose Psilocybin Treatment for Major Depressive Disorder

医学 灵霉素 重性抑郁障碍 加药 精神科 不利影响 安慰剂 自杀意念 萧条(经济学) 双相情感障碍 抗抑郁药 评定量表 内科学 毒物控制 心理学 致幻剂 焦虑 心情 伤害预防 发展心理学 替代医学 环境卫生 病理 经济 宏观经济学
作者
Charles L. Raison,Gerard Sanacora,Joshua Woolley,Keith G. Heinzerling,Boadie W. Dunlop,Randall Brown,Rishi Kakar,Michael Hassman,Rupal Trivedi,Reid Robison,Natalie Gukasyan,Sandeep Nayak,Xiao Hu,Kelley C. O’Donnell,Benjamin Kelmendi,Jordan Sloshower,Andrew Penn,Ellen Bradley,Daniel F. Kelly,Tanja Mletzko,Christopher R. Nicholas,Paul R. Hutson,Gary Tarpley,Malynn Utzinger,Kelsey Lenoch,Kasia Warchol,Theraysa Gapasin,M. Davis,Courtney Nelson-Douthit,Steffanie H Wilson,Carrie Brown,William Linton,Stephen Ross,Roland R. Griffiths
出处
期刊:JAMA [American Medical Association]
卷期号:330 (9): 843-843 被引量:32
标识
DOI:10.1001/jama.2023.14530
摘要

Importance Psilocybin shows promise as a treatment for major depressive disorder (MDD). Objective To evaluate the magnitude, timing, and durability of antidepressant effects and safety of a single dose of psilocybin in patients with MDD. Design, Setting, and Participants In this phase 2 trial conducted between December 2019 and June 2022 at 11 research sites in the US, participants were randomized in a 1:1 ratio to receive a single dose of psilocybin vs niacin placebo administered with psychological support. Participants were adults aged 21 to 65 years with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition diagnosis of MDD of at least 60 days’ duration and moderate or greater symptom severity. Exclusion criteria included history of psychosis or mania, active substance use disorder, and active suicidal ideation with intent. Participants taking psychotropic agents who otherwise met inclusion/exclusion criteria were eligible following medication taper. Primary and secondary outcomes and adverse events (AEs) were assessed at baseline (conducted within 7 days before dosing) and at 2, 8, 15, 29, and 43 days after dosing. Interventions Interventions were a 25-mg dose of synthetic psilocybin or a 100-mg dose of niacin in identical-appearing capsules, each administered with psychological support. Main Outcomes and Measures The primary outcome was change in central rater–assessed Montgomery-Asberg Depression Rating Scale (MADRS) score (range, 0-60; higher scores indicate more severe depression) from baseline to day 43. The key secondary outcome measure was change in MADRS score from baseline to day 8. Other secondary outcomes were change in Sheehan Disability Scale score from baseline to day 43 and MADRS-defined sustained response and remission. Participants, study site personnel, study sponsor, outcome assessors (raters), and statisticians were blinded to treatment assignment. Results A total of 104 participants (mean [SD] age, 41.1 [11.3] years; 52 [50%] women) were randomized (51 to the psilocybin group and 53 to the niacin group). Psilocybin treatment was associated with significantly reduced MADRS scores compared with niacin from baseline to day 43 (mean difference,−12.3 [95% CI, −17.5 to −7.2]; P <.001) and from baseline to day 8 (mean difference, −12.0 [95% CI, −16.6 to −7.4]; P < .001). Psilocybin treatment was also associated with significantly reduced Sheehan Disability Scale scores compared with niacin (mean difference, −2.31 [95% CI, 3.50-1.11]; P < .001) from baseline to day 43. More participants receiving psilocybin had sustained response (but not remission) than those receiving niacin. There were no serious treatment-emergent AEs; however, psilocybin treatment was associated with a higher rate of overall AEs and a higher rate of severe AEs. Conclusions and Relevance Psilocybin treatment was associated with a clinically significant sustained reduction in depressive symptoms and functional disability, without serious adverse events. These findings add to increasing evidence that psilocybin—when administered with psychological support—may hold promise as a novel intervention for MDD. Trial Registration ClinicalTrials.gov Identifier: NCT03866174
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Eric完成签到 ,获得积分10
4秒前
伶俐海安完成签到 ,获得积分10
8秒前
宇文非笑完成签到 ,获得积分10
15秒前
科研佟完成签到 ,获得积分10
16秒前
zhang完成签到 ,获得积分10
25秒前
yi完成签到,获得积分10
37秒前
mgqqlwq完成签到,获得积分10
1分钟前
April完成签到 ,获得积分10
1分钟前
MMY完成签到,获得积分10
1分钟前
1分钟前
1分钟前
童童应助科研通管家采纳,获得10
1分钟前
啦啦啦完成签到 ,获得积分10
1分钟前
长卿123发布了新的文献求助10
1分钟前
FashionBoy应助mgqqlwq采纳,获得10
1分钟前
hhh2018687完成签到,获得积分10
1分钟前
Matthew完成签到 ,获得积分10
1分钟前
香蕉觅云应助崔西采纳,获得10
1分钟前
xhsz1111完成签到 ,获得积分10
1分钟前
可爱的函函应助球球球心采纳,获得10
2分钟前
Amosummer完成签到,获得积分10
2分钟前
执着易形完成签到 ,获得积分10
2分钟前
谁能拒绝周杰伦呢完成签到 ,获得积分10
2分钟前
Snow完成签到 ,获得积分10
3分钟前
papertanchishe完成签到,获得积分10
3分钟前
3分钟前
matilda完成签到 ,获得积分10
4分钟前
方方发布了新的文献求助10
4分钟前
吴戴夫完成签到,获得积分10
4分钟前
刘玲完成签到 ,获得积分10
4分钟前
李爱国应助方方采纳,获得10
4分钟前
认真的飞扬完成签到 ,获得积分10
4分钟前
大海来也12138完成签到 ,获得积分10
4分钟前
方方完成签到,获得积分10
4分钟前
mmichaell完成签到,获得积分10
5分钟前
飞云完成签到 ,获得积分10
5分钟前
5分钟前
5分钟前
5分钟前
mgqqlwq发布了新的文献求助10
5分钟前
高分求助中
Un calendrier babylonien des travaux, des signes et des mois: Séries iqqur îpuš 1036
Sustainable Land Management: Strategies to Cope with the Marginalisation of Agriculture 1000
Corrosion and Oxygen Control 600
Python Programming for Linguistics and Digital Humanities: Applications for Text-Focused Fields 500
Heterocyclic Stilbene and Bibenzyl Derivatives in Liverworts: Distribution, Structures, Total Synthesis and Biological Activity 500
重庆市新能源汽车产业大数据招商指南(两链两图两池两库两平台两清单两报告) 400
Division and square root. Digit-recurrence algorithms and implementations 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2545949
求助须知:如何正确求助?哪些是违规求助? 2175672
关于积分的说明 5600226
捐赠科研通 1896383
什么是DOI,文献DOI怎么找? 946268
版权声明 565379
科研通“疑难数据库(出版商)”最低求助积分说明 503557